Madrigal Pharmaceuticals is a biopharmaceutical company focused on therapeutics for metabolic dysfunction-associated steatohepatitis (MASH). Its lead product, Rezdiffra (resmetirom), is a once-daily oral thyroid hormone receptor beta agonist that received FDA accelerated approval in March 2024 and European Commission conditional marketing authorization in August 2025, becoming the first approved therapy for noncirrhotic MASH with moderate to advanced liver fibrosis. The company generated $958.4 million in product revenue in 2025 and is building a pipeline including MGL-2086, ervogastat, and six siRNA programs.
Q2 FY2026 — expected 2026-08-15
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-19 | 2025-12-31 | 0001628280-26-009514 | EDGAR | 84K words |
| 2025-02-26 | 2024-12-31 | 0001628280-25-007980 | EDGAR | 77K words |
| 2024-02-28 | 2023-12-31 | 0001628280-24-007376 | EDGAR | 63K words |
| 2023-02-23 | 2022-12-31 | 0001193125-23-045575 | EDGAR | — |
| 2022-02-24 | 2021-12-31 | 0001193125-22-051569 | EDGAR | — |
| 2021-02-25 | 2020-12-31 | 0001193125-21-056164 | EDGAR | — |
| 2020-02-26 | 2019-12-31 | 0001193125-20-049021 | EDGAR | — |
| 2019-02-27 | 2018-12-31 | 0001047469-19-000725 | EDGAR | — |
| 2018-03-13 | 2017-12-31 | 0001047469-18-001557 | EDGAR | — |
| 2017-03-31 | 2016-12-31 | 0001047469-17-002260 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-07-30 | 2026-06-30 | 0001628280-26-050845 | EDGAR | 25K words |
| 2025-11-04 | 2025-09-30 | 0001628280-25-048559 | EDGAR | 22K words |
| 2025-08-05 | 2025-06-30 | 0001628280-25-037613 | EDGAR | 23K words |
| 2025-05-01 | 2025-03-31 | 0001628280-25-021356 | EDGAR | 19K words |
| 2024-10-31 | 2024-09-30 | 0001628280-24-044445 | EDGAR | 22K words |
| 2024-08-07 | 2024-06-30 | 0001628280-24-035400 | EDGAR | 21K words |
| 2024-05-07 | 2024-03-31 | 0001628280-24-020865 | EDGAR | 19K words |
| 2023-11-06 | 2023-09-30 | 0001193125-23-270803 | EDGAR | 22K words |
| 2023-08-08 | 2023-06-30 | 0001193125-23-205535 | EDGAR | 20K words |
| 2023-05-09 | 2023-03-31 | 0001193125-23-138863 | EDGAR | — |
| 2022-11-03 | 2022-09-30 | 0001193125-22-276468 | EDGAR | — |
| 2022-08-04 | 2022-06-30 | 0001193125-22-211757 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-08-12 | 0001628280-26-055962 | EDGAR | 1K words |
| 2026-07-30 | 0001628280-26-050775 | EDGAR | 2K words |
| 2026-02-19 | 0001628280-26-009476 | EDGAR | 2K words |
| 2026-01-30 | 0001104659-26-008698 | EDGAR | 1K words |
| 2025-12-11 | 0001628280-25-056533 | EDGAR | 1K words |
| 2025-11-04 | 0001628280-25-048525 | EDGAR | 2K words |
| 2025-08-05 | 0001628280-25-037596 | EDGAR | 3K words |
| 2025-07-30 | 0001104659-25-071928 | EDGAR | 1K words |
| 2025-07-22 | 0001628280-25-035506 | EDGAR | 1K words |
| 2025-06-20 | 0001628280-25-032358 | EDGAR | 1K words |
289 total filings indexed. 257 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001157601 |
| Ticker | MDGL |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.madrigalpharma.com |
| Listed | 2007-02-06 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/MDGL (~200 tokens, structured JSON with cryptographic provenance)